Heron Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Heron Therapeutics generated cash of -$58,789,000, which is more than the previous year. Cash used in financing activities reached the amount of $54,107,000 last year. Net change in cash is therefore $13,313,000.
Cash Flow
| 2014 | -60.28M | -1.43M | 62.10M |
|---|---|---|---|
| 2015 | -78.52M | -56.96M | 137.99M |
| 2016 | -134.09M | 14.87M | 57.45M |
| 2017 | -170.3M | 7.73M | 293.73M |
| 2018 | -191.80M | -278.55M | 357.60M |
| 2019 | -124.58M | -21.78M | 186.42M |
| 2020 | -184.82M | 208.95M | 9.10M |
| 2021 | -203.35M | 32.72M | 156.02M |
| 2022 | -146.91M | -3.32M | 75.05M |
| 2023 | -58.78M | 17.99M | 54.10M |
HRTX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 15.36M | 90.54M | 105.13M | 71.89M | 31.83M | 144.58M | 13.41M | 75.18M | 72.67M | 72.28M |
Operating activities | ||||||||||
Net income | -110.55M | -182.02M | -220.68M | -227.27M | -204.74M | -178.84M | -197.48M | -173.14M | -97.59M | -76.36M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 2.89M | 2.88M | 3.02M | 2.84M | 2.04M | 1.51M | 1.53M | 1.09M | 734K | 578K |
Stock-based compensation expense | 32.85M | 42.98M | 46.85M | 50.21M | 51.41M | 0 | 30.53M | 25.95M | 14.36M | 8.06M |
| Deferred income tax benefit | 32.85M | 42.98M | 46.85M | 50.21M | 51.41M | 0 | 30.53M | 25.95M | 14.36M | 8.06M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -8.08M | -16.55M | 6.35M | -1.97M | 24.77M | -22.77M | -39.91M | -1.96M | 0 | 0 |
Inventories | 12.46M | -6.19M | -6.47M | -16.93M | 14.06M | -29.12M | -4.76M | -5.34M | 0 | 0 |
Accounts payable | 15K | -578K | 3.27M | -2.23M | -14.10M | -1.90M | 11.95M | 3.51M | 751K | 1.28M |
Cash generated by operating activities | -58.78M | -146.91M | -203.35M | -184.82M | -124.58M | -191.80M | -170.3M | -134.09M | -78.52M | -60.28M |
Investing activities | ||||||||||
Purchases Of Investments | -87.65M | -145.68M | -129.22M | -134.00M | -477.03M | -497.10M | -121.57M | -43.31M | -56.11M | 0 |
Investments In Property Plant And Equipment | -1.54M | -1.82M | -3.02M | -6.81M | -7.15M | -9.17M | -2.55M | -3.13M | -1.08M | -1.43M |
Acquisitions Net | 0 | 227K | 32K | -215.76M | -25K | 25K | 78K | 0 | 241K | 0 |
Cash generated by investing activities | 17.99M | -3.32M | 32.72M | 208.95M | -21.78M | -278.55M | 7.73M | 14.87M | -56.96M | -1.43M |
Financing activities | ||||||||||
Common Stock Issued | 29.75M | 75.14M | 7.06M | 9.07M | 162.15M | 0 | 306.27M | 7.45M | 128.19M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 24.35M | 0 | -148.96M | -26K | 0 | 0 | -25M | -50M | 0 | 0 |
Cash used in financing activities | 54.10M | 75.05M | 156.02M | 9.10M | 186.42M | 357.60M | 293.73M | 57.45M | 137.99M | 62.10M |
Net Change In Cash | 13.31M | -75.17M | -14.59M | 33.24M | 40.06M | -112.74M | 131.16M | -61.76M | 2.50M | 388K |
Cash at end of period | 28.67M | 15.36M | 90.54M | 105.13M | 71.89M | 31.83M | 144.58M | 13.41M | 75.18M | 72.67M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |